Review Article | Published:

A network dysfunction perspective on neurodegenerative diseases

Nature volume 443, pages 768773 (19 October 2006) | Download Citation

Subjects

Abstract

Patients with Alzheimer's disease or other neurodegenerative disorders show remarkable fluctuations in neurological functions, even during the same day. These fluctuations cannot be caused by sudden loss or gain of nerve cells. Instead, it is likely that they reflect variations in the activity of neural networks and, perhaps, chronic intoxication by abnormal proteins that the brain is temporarily able to overcome. These ideas have far-reaching therapeutic implications.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Prospects for neurology and psychiatry. J. Am. Med. Assoc. 285, 594–600 (2001).

  2. 2.

    , , , & Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J. Neurol. Neurosurg. Psychiatry 75, 382–387 (2004).

  3. 3.

    et al. The clinician assessment of fluctuation and the one day fluctuation assessment scale. Two methods to assess fluctuating confusion in dementia. Br. J. Psychiatry 177, 252–256 (2000).

  4. 4.

    et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology 54, 1616–1625 (2000).

  5. 5.

    et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863–1872 (2005).

  6. 6.

    , , & Delirium in dementia. Int. J. Geriatr. Psychiatry 13, 49–56 (1998).

  7. 7.

    et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–580 (1991).

  8. 8.

    & Life and death of neurons in the aging brain. Science 278, 412–419 (1997).

  9. 9.

    et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann. Neurol. 49, 202–213 (2001).

  10. 10.

    et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58, 1395–1402 (2001).

  11. 11.

    et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 63, 584–588 (2006).

  12. 12.

    Antipsychotic drug-induced movement disorders. Can. J. Neurol. Sci. 30 (Suppl. 1), S101–S107 (2003).

  13. 13.

    & Antibasal ganglia antibodies and their relevance to movement disorders. Curr. Opin. Neurol. 17, 425–432 (2004).

  14. 14.

    Is your brain really necessary? Science 210, 1232–1234 (1980).

  15. 15.

    , & Nervous system reorganization following injury. Neuroscience 111, 761–773 (2002).

  16. 16.

    , & Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26, 215–221 (2003).

  17. 17.

    What is cognitive reserve? Theory and research application of the reserve concept. J. Int. Neuropsychol. Soc. 8, 448–460 (2002).

  18. 18.

    Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 44, 195–208 (2004).

  19. 19.

    , , , & Cognitive strategies dependent on the hippocampus and caudate nucleus in human navigation: variability and change with practice. J. Neurosci. 23, 5945–5952 (2003).

  20. 20.

    , , & Routes to remembering: the brains behind superior memory. Nature Neurosci. 6, 90–95 (2003).

  21. 21.

    , & Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5644–5651 (2006).

  22. 22.

    Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202–208 (2005).

  23. 23.

    , & Similar network activity from disparate circuit parameters. Nature Neurosci. 7, 1345–1352 (2004).

  24. 24.

    & Degeneracy and complexity in biological systems. Proc. Natl Acad. Sci. USA 98, 13763–13768 (2001).

  25. 25.

    , , & Plasticity of the nigropallidal pathway in Parkinson's disease. Ann. Neurol. 53, 206–213 (2003).

  26. 26.

    & Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181–193 (2004).

  27. 27.

    & Modulation of neurodegeneration by molecular chaperones. Nature Rev. Neurosci. 6, 11–22 (2005).

  28. 28.

    , , & Anticonvulsants attenuate amyloid β-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol. Aging 16, 187–198 (1995).

  29. 29.

    , & Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 45, 583–595 (2004).

  30. 30.

    & Inflammation in neurodegenerative disease — a double-edged sword. Neuron 35, 419–432 (2002).

  31. 31.

    Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58, 495–505 (2005).

  32. 32.

    , & Alzheimer's disease and Aβ toxicity: from top to bottom. Nature Rev. Neurosci. 2, 595–598 (2001).

  33. 33.

    Pathways towards and away from Alzheimer's disease. Nature 430, 631–639 (2004).

  34. 34.

    , , & Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin. Sci. (Lond.) 110, 73–88 (2006).

  35. 35.

    Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals. Neurobiol. Aging 24, 1047–1062 (2003).

  36. 36.

    , , , & Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci. 27, 691–697 (2004).

  37. 37.

    , & Gene–environment interactions, neuronal dysfunction and pathological plasticity in Huntington's disease. Clin. Exp. Pharmacol. Physiol. 32, 1007–1019 (2005).

  38. 38.

    et al. Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice. Cell 120, 701–713 (2005).

  39. 39.

    Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24, 521–529 (1999).

  40. 40.

    , & Amyloid β-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 10, 229–248 (2004).

  41. 41.

    Pouring oil into the fire? On the conundrum of the beneficial effects of NMDA receptor antagonists in Alzheimer disease. Psychopharmacology (Berl.) 9, 151–153 (2005).

  42. 42.

    et al. SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. J. Biol. Chem. 280, 40364–40374 (2005).

  43. 43.

    , , , & A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nature Genet. 37, 526–531 (2005).

  44. 44.

    & Molecular profile of reactive astrocytes — implications for their role in neurologic disease. Neuroscience 54, 15–36 (1993).

  45. 45.

    et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl Acad. Sci. USA 100, 9572–9577 (2003).

  46. 46.

    et al. Impaired cross-modal inhibition in Alzheimer disease. PLoS Med. 2, 986–995 (2005).

  47. 47.

    et al. Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J. Neurosci. 25, 9686–9693 (2005).

  48. 48.

    Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease. J. Neurochem. 96, 609–623 (2006).

  49. 49.

    , , , & Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805–810 (2004).

  50. 50.

    & Inhibitory neuronal activity can compensate for adverse effects of β-amyloid in hippocampal neurons. Brain Res. 786, 115–121 (1998).

  51. 51.

    et al. Ablation of cerebellar Golgi cells disrupts synaptic integration involving GABA inhibition and NMDA receptor activation in motor coordination. Cell 95, 17–27 (1998).

  52. 52.

    et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 51, 145–155 (2002).

  53. 53.

    Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease? Trends Neurosci. 27, 245–249 (2004).

  54. 54.

    et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65, 404–411 (2005).

  55. 55.

    Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr. Top. Microbiol. Immunol. 296, 1–17 (2005).

  56. 56.

    , , & Adult epilepsy. Lancet 367, 1087–1100 (2006).

  57. 57.

    & Cognitive decline in severe intractable epilepsy. Epilepsia 46, 1780–1787 (2005).

  58. 58.

    et al. Mortality of epilepsy in developed countries: a review. Epilepsia 46 (Suppl. 11), 18–27 (2005).

  59. 59.

    Present and future drug treatment for Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 76, 1472–1478 (2005).

  60. 60.

    , & Current pharmacotherapy for Alzheimer's disease. Annu. Rev. Med. 57, 513–533 (2006).

  61. 61.

    , & Functional neurochemistry of Alzheimer's disease. Curr. Pharm. Des. 10, 265–293 (2004).

  62. 62.

    & Juvenile onset Huntington's disease — clinical and research perspectives. Ment. Retard. Dev. Disabil. Res. Rev. 7, 153–157 (2001).

  63. 63.

    et al. Can Alzheimer's disease and dementias with Lewy bodies be distinguished clinically? J. Geriatr. Psychiatry Neurol. 16, 245–250 (2003).

  64. 64.

    et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47, 867–872 (2006).

  65. 65.

    et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493–506 (1996).

  66. 66.

    , , , & Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci. Lett. 367, 164–167 (2004).

  67. 67.

    Calcium-regulated signaling pathways: role in amyloid β-induced synaptic dysfunction. Neuromolecular Med. 6, 53–64 (2004).

  68. 68.

    & Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545–584 (2003).

  69. 69.

    et al. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J. Neurosci. 2, 986–993 (2003).

  70. 70.

    et al. Alzheimer's patients engage an alternative network during a memory task. Ann. Neurol. 58, 870–879 (2005).

  71. 71.

    Synaptic mechanisms of the cerebellar cortical network. Trends Neurosci. 28, 93–100 (2005).

  72. 72.

    & Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's Disease. Genes Brain Behav. 4, 173–196 (2005).

  73. 73.

    et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979–982 (2000).

  74. 74.

    et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982–985 (2000).

  75. 75.

    et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nature Neurosci. 5, 452–457 (2002).

  76. 76.

    et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331–6335 (2002).

  77. 77.

    , & Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57–66 (2000).

  78. 78.

    et al. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J. Neurosci. 21, 8772–8781 (2001).

  79. 79.

    et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857–868 (2005).

  80. 80.

    , & Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta 1739, 331–354 (2005).

  81. 81.

    et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476–481 (2005).

  82. 82.

    et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25, 9694–9703 (2005).

  83. 83.

    et al. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J. Neurosci. 23, 5219–5226 (2003).

  84. 84.

    et al. Synaptic targeting by Alzheimer's-related amyloid β oligomers. J. Neurosci. 24, 10191–10200 (2004).

  85. 85.

    , , , & Cell adhesion molecules in neural plasticity and pathology: similar mechanisms, distinct organizations? Prog. Neurobiol. 55, 659–669 (1998).

  86. 86.

    , , , & Block of long-term potentiation by naturally secreted and synthetic amyloid β-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 24, 3370–3378 (2004).

  87. 87.

    et al. Regulation of NMDA receptor trafficking by amyloid-β. Nature Neurosci. 8, 1051–1058 (2005).

  88. 88.

    & The role of nicotinic acetylcholine receptors in Alzheimer's disease. J. Physiol. (Paris) 99, 172–179 (2006).

  89. 89.

    , & β-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J. Biol. Chem. 280, 31746–31753 (2005).

  90. 90.

    Mitogen-activated protein kinases and the evolution of Alzheimer's: a revolutionary neurogenetic axis for therapeutic intervention? Prog. Neurobiol. 73, 359–377 (2004).

  91. 91.

    Tau and src family tyrosine kinases. Biochim. Biophys. Acta 1739, 323–330 (2005).

  92. 92.

    , & Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease? Neuroreport 16, 1725–1730 (2005).

  93. 93.

    et al. Soluble β-amyloid1–40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J. Neurosci. 25, 11061–11070 (2005).

  94. 94.

    et al. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis. 20, 187–198 (2005).

  95. 95.

    et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl Acad. Sci. USA 96, 3228–3233 (1999).

  96. 96.

    et al. High-level neuronal expression of Aβ1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050–4058 (2000).

  97. 97.

    , , & Dendrite and dendritic spine alterations in Alzheimer models. J. Neurocytol. 33, 377–387 (2004).

  98. 98.

    et al. APP processing and synaptic function. Neuron 37, 925–937 (2003).

  99. 99.

    et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neurosci. 2, 271–276 (1999).

  100. 100.

    et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).

Download references

Acknowledgements

We thank S. Finkbeiner for helpful discussion of the Huntington's disease literature, J. Carroll for preparation of graphics, G. Howard and S. Ordway for editorial review, and D. McPherson and L. Manuntag for administrative assistance. This work was supported by grants (to L.M.) from the National Institutes of Health.

Author information

Affiliations

  1. Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, California 94158, USA.

    • Jorge J. Palop
    • , Jeannie Chin
    •  & Lennart Mucke

Authors

  1. Search for Jorge J. Palop in:

  2. Search for Jeannie Chin in:

  3. Search for Lennart Mucke in:

Competing interests

L.M. has been consulted by Merck and has received honoraria for lectures from Elan, Amgen and Pfizer.

Corresponding author

Correspondence to Lennart Mucke.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nature05289

Reprints and permissions information is available at npg.nature.com/reprints and permissions.

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing